These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 28783167)
1. Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3. Zhang T; Li J; Yin F; Lin B; Wang Z; Xu J; Wang H; Zuo D; Wang G; Hua Y; Cai Z Oncogene; 2017 Nov; 36(47):6627-6639. PubMed ID: 28783167 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells. Zuo D; Shogren KL; Zang J; Jewison DE; Waletzki BE; Miller AL; Okuno SH; Cai Z; Yaszemski MJ; Maran A J Exp Clin Cancer Res; 2018 Oct; 37(1):244. PubMed ID: 30286779 [TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of toosendanin on oral squamous cell carcinoma via suppression of p-STAT3. Wu Y; Chen L; Feng C; Wang T; He S; Zheng D; Lin L BMC Oral Health; 2023 Nov; 23(1):846. PubMed ID: 37946196 [TBL] [Abstract][Full Text] [Related]
4. Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway. Wang S; Wang Y; Huang Z; Wei H; Wang X; Shen R; Lan W; Zhong G; Lin J Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1670-1680. PubMed ID: 34693451 [TBL] [Abstract][Full Text] [Related]
5. Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma. Ji XL; He M Aging (Albany NY); 2019 Aug; 11(15):5848-5863. PubMed ID: 31422383 [TBL] [Abstract][Full Text] [Related]
6. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3. Zheng B; Ren T; Huang Y; Guo W Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166 [TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701. Nishisaka F; Taniguchi K; Tsugane M; Hirata G; Takagi A; Asakawa N; Kurita A; Takahashi H; Ogo N; Shishido Y; Asai A Cancer Sci; 2020 May; 111(5):1774-1784. PubMed ID: 32112605 [TBL] [Abstract][Full Text] [Related]
8. STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma. Oi T; Asanuma K; Matsumine A; Matsubara T; Nakamura T; Iino T; Asanuma Y; Goto M; Okuno K; Kakimoto T; Yada Y; Sudo A Int J Oncol; 2016 Dec; 49(6):2275-2284. PubMed ID: 27840900 [TBL] [Abstract][Full Text] [Related]
9. Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth. Li X; Ma H; Li L; Chen Y; Sun X; Dong Z; Liu JY; Zhu W; Zhang JT Oncogene; 2018 May; 37(18):2469-2480. PubMed ID: 29456240 [TBL] [Abstract][Full Text] [Related]
11. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Lin L; Hutzen B; Zuo M; Ball S; Deangelis S; Foust E; Pandit B; Ihnat MA; Shenoy SS; Kulp S; Li PK; Li C; Fuchs J; Lin J Cancer Res; 2010 Mar; 70(6):2445-54. PubMed ID: 20215512 [TBL] [Abstract][Full Text] [Related]
12. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Yu PY; Gardner HL; Roberts R; Cam H; Hariharan S; Ren L; LeBlanc AK; Xiao H; Lin J; Guttridge DC; Mo X; Bennett CE; Coss CC; Ling Y; Phelps MA; Houghton P; London CA PLoS One; 2017; 12(7):e0181885. PubMed ID: 28750090 [TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3. Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780 [TBL] [Abstract][Full Text] [Related]
14. 4-Methoxydalbergione suppresses growth and induces apoptosis in human osteosarcoma cells in vitro and in vivo xenograft model through down-regulation of the JAK2/STAT3 pathway. Park KR; Yun HM; Quang TH; Oh H; Lee DS; Auh QS; Kim EC Oncotarget; 2016 Feb; 7(6):6960-71. PubMed ID: 26755649 [TBL] [Abstract][Full Text] [Related]
15. Glaucocalyxin A-induced oxidative stress inhibits the activation of STAT3 signaling pathway and suppresses osteosarcoma progression in vitro and in vivo. Mao M; Zhang T; Wang Z; Wang H; Xu J; Yin F; Wang G; Sun M; Wang Z; Hua Y; Cai Z Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1214-1225. PubMed ID: 30659925 [TBL] [Abstract][Full Text] [Related]
16. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Onimoe GI; Liu A; Lin L; Wei CC; Schwartz EB; Bhasin D; Li C; Fuchs JR; Li PK; Houghton P; Termuhlen A; Gross T; Lin J Invest New Drugs; 2012 Jun; 30(3):916-26. PubMed ID: 21340507 [TBL] [Abstract][Full Text] [Related]
17. Catalpol suppresses osteosarcoma cell proliferation through blocking epithelial-mesenchymal transition (EMT) and inducing apoptosis. Wang L; Xue GB Biochem Biophys Res Commun; 2018 Jan; 495(1):27-34. PubMed ID: 29032182 [TBL] [Abstract][Full Text] [Related]
18. Chlorogenic acid inhibits osteosarcoma carcinogenesis via suppressing the STAT3/Snail pathway. Zhang F; Yin G; Han X; Jiang X; Bao Z J Cell Biochem; 2019 Jun; 120(6):10342-10350. PubMed ID: 30582213 [TBL] [Abstract][Full Text] [Related]
19. Toosendanin induces hepatotoxicity by restraining autophagy and lysosomal function through inhibiting STAT3/CTSC axis. Luo L; Ni J; Zhang J; Lin J; Chen S; Shen F; Huang Z Toxicol Lett; 2024 Apr; 394():102-113. PubMed ID: 38460807 [TBL] [Abstract][Full Text] [Related]
20. Bruceantinol targeting STAT3 exerts promising antitumor effects in in vitro and in vivo osteosarcoma models. Miao J; Chen S; Cao H; Ding Z; Li Y; Wang W; Nundlall K; Deng Y; Li J Mol Carcinog; 2024 Jun; 63(6):1133-1145. PubMed ID: 38426797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]